TCL Archive Predicant, Correlogic executives contradict scientists’ claim that firms didn’t appear to compete. June 25, 2004
TCL Archive Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial April 27, 2012
TCL Archive Biotherapeutics Reports LAK/IL-2 Toxicity Reduced With Constant Infusion Of IL-2 April 17, 1987
TCL Archive ‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’ September 20, 1991
